Nelson Hamerschlak

Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases

BACKGROUND: Talquetamab, a GPRC5D-targeting bispecific antibody, produces high response rates in relapsed/refractory multiple myeloma (RRMM) but is frequently associated with oral adverse effects, most commonly dysgeusia and xerostomia, which can impair nutrition and quality of l...